{"id":38880,"date":"2026-06-29T09:57:00","date_gmt":"2026-06-29T13:57:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38880"},"modified":"2026-05-12T08:31:28","modified_gmt":"2026-05-12T12:31:28","slug":"patent-term-extension-u-s-vs-eu-spc-vs-japan-the-complete-strategic-guide-for-pharma-ip-teams","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/patent-term-extension-u-s-vs-eu-spc-vs-japan-the-complete-strategic-guide-for-pharma-ip-teams\/","title":{"rendered":"Patent Term Extension U.S. vs. EU SPC vs. Japan: The Complete Strategic Guide for Pharma IP Teams"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Every blockbuster drug faces the same structural threat: the clock runs out on patent protection before the manufacturer has fully recovered the cost of bringing it to market. Patent term extension systems exist to fix that problem, but the U.S., European Union, and Japanese approaches differ enough that a strategy optimized for one jurisdiction can be actively counterproductive in another.<\/p>\n\n\n\n

This guide compares those three systems in enough granular detail to inform decisions made by IP counsel, business development teams, generic manufacturers planning market entry, and investors pricing loss-of-exclusivity (LOE) risk. It covers the statutory mechanics, eligibility traps, strategic sequencing, litigation patterns, and the ways brand manufacturers use or misuse each system to hold off generic competition.<\/p>\n\n\n\n

Where relevant, the analysis references DrugPatentWatch, the industry’s most-used database for monitoring pharmaceutical patent expiry, Paragraph IV certifications, and Orange Book listings \u2014 tools that have become essential for both originator IP teams and generic challengers mapping a landscape that changes faster than most static databases can track.<\/p>\n\n\n\n

\n\n\n\n

What Is Patent Term Extension and Why Does It Exist?<\/strong><\/h2>\n\n\n\n

Patent term extension (PTE) compensates originator pharmaceutical manufacturers for the regulatory approval time that erodes a drug’s effective patent life. Without it, a 20-year patent filed before clinical trials began might leave fewer than eight years of post-approval exclusivity after accounting for Phase I, II, and III development plus FDA or EMA review.<\/p>\n\n\n\n

The rationale is economic. If patent protection expires before a product has recovered its R&D investment, the incentive structure for developing new drugs weakens. The U.S. Congress addressed this in 1984 through the Drug Price Competition and Patent Term Restoration Act (the Hatch-Waxman Act), which created the U.S. Patent Term Extension under 35 U.S.C. \u00a7 156. The EU created the Supplementary Protection Certificate (SPC) regime in 1992 through Council Regulation (EEC) No. 1768\/92, later consolidated in Regulation (EC) No. 469\/2009. Japan’s patent term extension system operates under Article 67-2 of the Japanese Patent Act, amended in 1987 and revised in 2021.<\/p>\n\n\n\n

Each system uses a different calculation method, imposes different eligibility requirements, and generates a different risk profile for generic manufacturers attempting to enter the market after the extension expires. What follows is a comparison detailed enough to be actionable.<\/p>\n\n\n\n

U.S. Patent Term Extension Under 35 U.S.C. \u00a7 156: How It Actually Works<\/strong><\/h2>\n\n\n\n

What Is the Maximum Extension Available Under U.S. Law?<\/strong><\/h3>\n\n\n\n

The maximum extension under U.S. law is five years, subject to an absolute cap: the total remaining patent term including the extension cannot exceed 14 years from the date of first commercial marketing approval.<\/p>\n\n\n\n

The calculation starts with the regulatory review period, which has two components. The first is the testing phase \u2014 time spent conducting clinical investigations after the patent was granted. The second is the approval phase \u2014 time between the date the New Drug Application (NDA) or Biologics License Application (BLA) was submitted and the date FDA approved it. Only half of the testing phase counts, but the entire approval phase counts.<\/p>\n\n\n\n

This structure produces some non-obvious outcomes. A product with a long clinical history but a fast FDA review will receive a shorter extension than one with a quick development timeline but a slow approval. Sponsors routinely discover that the five-year ceiling is more commonly hit by the 14-year total-term cap than by the raw calculation, particularly for drugs with strong Phase II data that moved quickly into Phase III.<\/p>\n\n\n\n

Patent Term Extensions apply only to one patent per drug product, and only to patents that claim the product (the active ingredient), a method of using the product, or the method of manufacturing the product. Process patents that do not directly claim the approved product are not eligible, and the application must be filed within 60 days of FDA approval. Missing that window waives the right entirely \u2014 there is no cure mechanism.<\/p>\n\n\n\n

Which Patents Qualify for U.S. PTE: Eligibility Traps That Trip Up IP Teams<\/strong><\/h3>\n\n\n\n

The patent must be in force, must not have previously been extended, and must not have previously been listed in the Orange Book for a different product. That last restriction is surprisingly common. When a single compound patent covers multiple approved products, only the first approval can generate a PTE for that patent. A company seeking PTE for a second indication or a new formulation of the same compound needs a different, product-specific patent to carry the extension.<\/p>\n\n\n\n

The statute also requires that the patent have not expired before the approval date. Applications for drugs that received approval in the final months of a patent’s 20-year term are occasionally caught by this, particularly when patent term adjustment calculations are disputed and the USPTO’s records lag behind.<\/p>\n\n\n\n

Patent Term Adjustment (PTA) under 35 U.S.C. \u00a7 154 is frequently confused with Patent Term Extension. PTA compensates for USPTO delays during prosecution; PTE compensates for FDA regulatory delays. They are calculated separately, and a patent can benefit from both. A drug like dupilumab (Dupixent, Regeneron\/Sanofi) sits on a patent portfolio that exploits this distinction \u2014 individual patents carry PTA adjustments for prosecution delays, while the product-level PTE was applied to a separate patent claiming the method of treatment to maximize the exclusivity runway into the 2030s.<\/p>\n\n\n\n

How the USPTO Reviews a PTE Application: Timeline and Disputes<\/strong><\/h3>\n\n\n\n

The USPTO, in consultation with FDA, calculates the extension. The process routinely takes 18 to 30 months \u2014 long enough that the extension certificate is often issued after the initial patent has expired. During that interim period, a bridge period applies: the patent is treated as if it has not expired, which is critical for enforcement purposes.<\/p>\n\n\n\n

The regulatory review period determination is done by FDA, which submits its finding to the USPTO. Disputes arise most often over the date the clinical investigation began (affecting the testing phase calculation) and whether certain post-approval activities should extend or shorten the review period. Genentech’s litigation over trastuzumab (Herceptin) PTE calculations illustrated how contested these determinations can become when the boundary between pre-approval and post-approval regulatory work is ambiguous.<\/p>\n\n\n\n

PTE and Orange Book Listing: What the Connection Means for Generic Challengers<\/strong><\/h4>\n\n\n\n

Once a PTE is granted, the extended patent is listed in the FDA Orange Book with its new expiration date. Any generic manufacturer filing an Abbreviated New Drug Application (ANDA) must certify against that patent. If the generic manufacturer believes the PTE was improperly granted \u2014 say, because the sponsor failed to act with due diligence during the regulatory review period, or because the patent does not actually claim the approved product \u2014 it can challenge the PTE as an affirmative defense in Hatch-Waxman litigation.<\/p>\n\n\n\n

This creates a litigation pathway that is structurally underused. Most ANDA challengers focus on patent invalidity or non-infringement; challenging the PTE grant itself requires a different legal theory and often different expert witnesses (regulatory historians, patent prosecutors). But when the underlying chemistry is solid, a PTE challenge can be the more promising avenue. Apotex v. Thompson and related cases in the early 2000s established that courts would review PTE grants, though the standard of review is deferential toward the USPTO’s factual determinations.<\/p>\n\n\n\n

EU Supplementary Protection Certificates: A Different Architecture Entirely<\/strong><\/h2>\n\n\n\n

SPC Regulation (EC) No. 469\/2009: What It Actually Grants<\/strong><\/h3>\n\n\n\n

An SPC is not an extension of the underlying patent. It is a separate right that comes into force when the patent expires and lasts for the period between the filing date of the patent and the date of the first marketing authorization in the EU, minus five years, subject to a maximum duration of five years.<\/p>\n\n\n\n

The practical effect is similar to a U.S. PTE \u2014 up to five extra years of exclusivity \u2014 but the mechanism is structurally distinct. The SPC is a national right, granted separately by each EU member state’s patent office, despite originating in EU regulation. A company seeking SPC protection across the EU must file in each country individually, pay each country’s fees, and navigate each country’s administrative idiosyncrasies within a fixed window following marketing authorization.<\/p>\n\n\n\n

The CJEU has used this fragmented enforcement structure to generate a body of SPC case law more voluminous and more internally contradictory than almost any other area of pharmaceutical IP law. Decisions from one member state tribunal interpreting the regulation’s requirements do not bind other member states, though CJEU preliminary rulings do bind everyone \u2014 and the CJEU has not always been consistent.<\/p>\n\n\n\n

What Constitutes the ‘Product’ for EU SPC Purposes: The Neurim and Teva Debates<\/strong><\/h3>\n\n\n\n

The most contested question in EU SPC law is what counts as the ‘product’ protected by an SPC \u2014 and specifically whether a new therapeutic application of an already-approved compound can support a fresh SPC.<\/p>\n\n\n\n

The CJEU’s Neurim Pharmaceuticals decision in 2012 created years of confusion by appearing to allow SPCs for known active ingredients approved for a new therapeutic use, provided the basic patent was limited to that new use. Neurim itself was melatonin (Circadin) being approved for insomnia in adults over 55, where the prior veterinary approval should have blocked a new SPC under conventional interpretation. The court’s reasoning invited aggressive application by other originators trying to revive protection for compounds approaching LOE.<\/p>\n\n\n\n

The 2021 CJEU ruling in Santen SA v. Directeur g\u00e9n\u00e9ral de l’Institut national de la propri\u00e9t\u00e9 industrielle (C-673\/18) effectively overturned Neurim, returning to a stricter interpretation: an SPC can only be granted for a marketing authorization that is the ‘first authorization to place the product on the market as a medicinal product,’ and a new therapeutic application does not generate that right when the compound has a prior approval. The ruling forced several originator companies to remodel their late-cycle SPC strategies for ophthalmic and CNS compounds where new-indication SPCs had been planned.<\/p>\n\n\n\n

How EU SPC Filing Deadlines Work \u2014 and the Consequences of Missing Them<\/strong><\/h3>\n\n\n\n

An SPC application must be filed within six months of the first marketing authorization in the EU or, if later, six months from the date the basic patent was granted. Both windows must be checked; the deadline is whichever comes later.<\/p>\n\n\n\n

Missing the deadline is fatal. There is no mechanism to restore the right through a late filing, and no doctrine analogous to equitable tolling. Companies with complex patent portfolios \u2014 multiple compound patents, formulation patents, method patents \u2014 must track each patent’s application window independently, because the six-month countdown resets for each patent that might serve as the ‘basic patent.’<\/p>\n\n\n\n

This creates a genuine administrative burden for companies with global patent families. A failure to file in Germany, France, or Italy can cost hundreds of millions in generic-delayed revenue for a major product. Post-merger IP audits routinely surface missed SPC windows as a due diligence finding, particularly in deals involving smaller biotech companies that lacked dedicated patent term management infrastructure.<\/p>\n\n\n\n

EU SPC for Combination Products: The Royalty Pharma and Sitagliptin Problem<\/strong><\/h3>\n\n\n\n

When a drug product is a fixed-dose combination of two active ingredients \u2014 one of which is known and one of which is new \u2014 the question is whether the SPC can cover the combination even if the basic patent claims only the new molecule.<\/p>\n\n\n\n

The CJEU addressed this in Royalty Pharma Collection Trust v. Deutsches Patent- und Markenamt (C-650\/17), which involved a compound patent on sitagliptin combined with metformin for the diabetes product Janumet (Merck Sharp & Dohme). The court confirmed that an SPC can be granted for a combination when both active ingredients were ‘specifically identifiable’ in the basic patent, even without explicit claims to the combination. ‘Specifically identifiable’ remains a source of ongoing dispute in national proceedings, particularly for biological combinations where the interaction between components is mechanistically complex.<\/p>\n\n\n\n

SPC Manufacturing Waiver: How the EU Created a Paradox for Export Markets<\/strong><\/h4>\n\n\n\n

In 2019, the EU introduced an SPC manufacturing waiver (Regulation (EU) 2019\/933, amending Regulation 469\/2009) to allow manufacturers to produce generic and biosimilar versions of SPC-protected products within EU territory, exclusively for export to non-EU markets or for stockpiling ahead of SPC expiry to enable immediate EU launch on day one.<\/p>\n\n\n\n

The waiver was a direct response to pressure from EU-based generic manufacturers, who argued that SPC protection was driving production to India and China while doing nothing to protect EU supply chains. Its implementation has been uneven. The notification requirements, the ‘safeguard clause’ restricting export to countries where the product is not patent-protected, and the day-one stockpiling calculation have all generated compliance questions that the European Medicines Agency and national authorities are still working through.<\/p>\n\n\n\n

For originator companies, the waiver represents a partial erosion of SPC value: the exclusivity over EU commercial sales remains, but the manufacturing monopoly that once came with it is gone. The strategic calculus for choosing which EU market to prioritize during SPC protection has shifted as a result.<\/p>\n\n\n\n

Japan Patent Term Extension: The Most Frequently Overlooked Major Market<\/strong><\/h2>\n\n\n\n

How Japan’s Patent Term Extension System Works Under Article 67-2 of the Patent Act<\/strong><\/h3>\n\n\n\n

Japan allows patent term extensions of up to five years when a product could not be worked during the patent term because regulatory approval was required. The extension compensates for the period during which the product was subject to regulatory review, calculated from the NDA filing date to the approval date.<\/p>\n\n\n\n

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is the regulatory body responsible for drug approvals; the Japan Patent Office (JPO) handles PTE applications. Unlike the U.S. system, where only one patent can be extended per product approval, Japan allows multiple patents covering the same product to receive independent extensions, provided each patent independently satisfies the eligibility criteria.<\/p>\n\n\n\n

This structural difference has made Japan a priority jurisdiction for companies with dense patent portfolios. A drug company with five patents covering a single product \u2014 one on the compound, one on the formulation, one on the manufacturing process, one on the dosing regimen, and one on a particular polymorph \u2014 can theoretically extend all five separately in Japan, creating a layered exclusivity structure that is much harder for generic manufacturers to navigate than the single-patent U.S. model.<\/p>\n\n\n\n

Japan PTE Calculation: Why the Numbers Often Differ From U.S. and EU Results<\/strong><\/h3>\n\n\n\n

Japan calculates the extension as the period during which the patent could not be worked due to regulatory requirements \u2014 specifically, the time between the clinical trial notification and the product approval. This differs from the U.S. approach, which uses both a testing phase (clinical investigation after patent grant) and an approval phase (NDA submission to approval).<\/p>\n\n\n\n

In practice, Japanese PTE periods for the same drug frequently come out shorter than the corresponding U.S. PTE. Japan’s PMDA has historically operated on faster review timelines than the FDA for some therapeutic categories, which compresses the regulatory review period that generates the extension. However, the ability to extend multiple patents per drug compensates for this difference from a commercial protection standpoint.<\/p>\n\n\n\n

A 2021 revision to the Patent Act introduced more detailed criteria for extension eligibility, including rules on what constitutes ‘working’ a patent for regulatory purposes and clarifications on how the review period is calculated when supplemental data submissions extend the approval timeline. The revisions were partly a response to originator companies attempting to extend the review period calculation by submitting voluminous supplemental data during review.<\/p>\n\n\n\n

Multi-Patent Extensions in Japan: Strategic Advantages and Generic Entry Complications<\/strong><\/h3>\n\n\n\n

The ability to hold multiple extended patents on a single drug creates a stacking problem for generic challengers in Japan. A generic manufacturer that invalidates or designs around the compound patent may find that the formulation patent or the polymorph patent remains in force under its own extension, effectively blocking market entry.<\/p>\n\n\n\n

Generic manufacturers in Japan have responded by filing multi-front patent challenges, attacking each extended patent independently while simultaneously filing for regulatory approval. This is expensive, and the cost has historically deterred all but the largest Japanese generic companies from challenging branded products during the SPC-equivalent window.<\/p>\n\n\n\n

The Japan Fair Trade Commission (JFTC) has periodically flagged the accumulation of patent term extensions on single products as a potential competition concern, particularly in cases where the underlying patents are of questionable validity. However, Japan has not yet developed a formal mechanism analogous to the EU’s SPC manufacturing waiver or the U.S.’s 30-month stay automatic trigger to structure the generic challenge process around these extended patents.<\/p>\n\n\n\n

Japan’s Patent Linkage System: How It Interacts With PTE<\/strong><\/h4>\n\n\n\n

Japan introduced a patent linkage system in 2009, requiring generic manufacturers to notify the originator when filing an application for a drug covered by a listed patent. Unlike the U.S. Hatch-Waxman system, Japan’s linkage mechanism does not automatically stay generic approval. The originator must seek a court injunction independently, and the generic application continues to be reviewed during litigation.<\/p>\n\n\n\n

This means that in Japan, the patent term extension creates the exclusivity period, but enforcement of that exclusivity during the extension window depends on the originator’s ability to obtain and maintain injunctive relief \u2014 a different risk calculus than in the U.S., where the 30-month automatic stay gives originators guaranteed protection regardless of injunction timing.<\/p>\n\n\n\n

U.S. PTE vs. EU SPC vs. Japan PTE: A Direct Comparison<\/strong><\/h2>\n\n\n\n
Feature<\/th>U.S. PTE (35 U.S.C. \u00a7 156)<\/th>EU SPC (Reg. 469\/2009)<\/th>Japan PTE (Art. 67-2)<\/th><\/tr><\/thead>
Maximum extension<\/td>5 years<\/td>5 years + 6 months (pediatric)<\/td>5 years<\/td><\/tr>
Patents extendable per product<\/td>One<\/td>One per member state<\/td>Multiple<\/td><\/tr>
Calculation basis<\/td>Testing phase (\u00bd) + approval phase<\/td>MA date minus patent filing date, minus 5 years<\/td>Clinical trial notification to approval<\/td><\/tr>
Filing deadline<\/td>60 days post-approval<\/td>6 months post-MA or post-patent grant<\/td>3 months post-approval<\/td><\/tr>
Administrative body<\/td>USPTO + FDA<\/td>National patent offices (EU-wide fragmented)<\/td>JPO + PMDA<\/td><\/tr>
Pediatric extension<\/td>6 months (Pediatric Exclusivity, not PTE)<\/td>6 months SPC extension under Reg. 1901\/2006<\/td>None<\/td><\/tr>
Generic challenge mechanism<\/td>ANDA Paragraph IV + 30-month stay<\/td>National court + manufacturing waiver<\/td>Notification + court injunction<\/td><\/tr>
Combination products<\/td>One-product limitation applies strictly<\/td>Complex CJEU case law (Royalty Pharma)<\/td>Extendable if approval covers combination<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How LOE Dates Are Calculated When Multiple Exclusivity Layers Stack<\/strong><\/h2>\n\n\n\n

What Is Loss of Exclusivity and How Do PTE\/SPC Dates Affect Generic Entry Timing?<\/strong><\/h3>\n\n\n\n

Loss of exclusivity refers to the date on which branded drug sales become subject to generic competition. For most pharmaceutical products, the LOE date is not a single date \u2014 it is a cluster of dates from different exclusivity mechanisms expiring at different times in different jurisdictions.<\/p>\n\n\n\n

A typical LOE analysis for a major drug in 2026 involves stacking the following: compound patent expiry, patent term extension or SPC expiry, data exclusivity expiry (five years in the U.S. for new chemical entities, 10 years in the EU under the 8+2+1 framework), pediatric exclusivity if applicable, and any regulatory marketing exclusivity (orphan, REMS-based, new dosage form). Only when all of these expire in a given jurisdiction can generic competition proceed without restriction.<\/p>\n\n\n\n

For Humira (adalimumab, AbbVie), the LOE structure across jurisdictions is one of the most studied examples in modern pharmaceutical IP. In the EU, biosimilar entry began in October 2018 following SPC expiry in most member states. In the U.S., the compound patent expired in December 2016, but AbbVie maintained exclusivity through a settlement-based royalty structure with biosimilar developers until January 2023 \u2014 a result partly enabled by the sheer volume of formulation, device, and method patents in the Humira patent thicket, none of which individually required a PTE but which collectively extended the effective commercial exclusivity well past the compound patent expiry.<\/p>\n\n\n\n

Teams using DrugPatentWatch regularly cross-reference Orange Book listings, patent expiry data, and Paragraph IV certification histories to construct a complete LOE timeline. The database aggregates this across jurisdictions at a level of granularity that internal IP team tracking systems often cannot match, particularly for out-licensed or co-promoted products where the IP ownership chain is complex.<\/p>\n\n\n\n

Pediatric Exclusivity in the U.S.: Why It Adds Six Months on Top of PTE \u2014 and Why That Matters<\/strong><\/h3>\n\n\n\n

In the U.S., pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA) adds six months to all existing exclusivity periods and patent protections, including any PTE. It does not extend the patent term directly \u2014 it blocks FDA from approving any competing application for six months after the PTE or other exclusivity expiry.<\/p>\n\n\n\n

This is different from the EU’s pediatric SPC extension, which adds six months directly to the SPC duration. The legal mechanism is different, but the commercial effect is broadly similar: six additional months of effective exclusivity following the submission of a pediatric investigation plan or pediatric study report, subject to FDA or EMA acceptance.<\/p>\n\n\n\n

Six months of exclusivity on a $5-billion-per-year drug generates roughly $2.5 billion in revenue. The ‘reward’ structure of pediatric exclusivity was designed to encourage pediatric development of adult-indication drugs; it has also become a standard item in brand manufacturers’ LOE-delay toolkit regardless of the commercial importance of pediatric use. Companies routinely conduct minimally necessary pediatric studies to earn the six-month window for high-revenue products even where the pediatric indication has marginal clinical significance.<\/p>\n\n\n\n

Paragraph IV Litigation Strategy Against PTE-Extended Patents<\/strong><\/h2>\n\n\n\n

What Is a Paragraph IV Certification Against an Extended Patent?<\/strong><\/h3>\n\n\n\n

A Paragraph IV certification is a generic manufacturer’s assertion that a patent listed in the FDA Orange Book \u2014 including a PTE-extended patent \u2014 is either invalid or will not be infringed by the generic product. Filing a Paragraph IV certification constitutes an act of patent infringement under 35 U.S.C. \u00a7 271(e)(2), which triggers the brand’s right to sue and an automatic 30-month stay of FDA approval pending resolution.<\/p>\n\n\n\n

Against a PTE-extended patent, Paragraph IV litigation has two strategic pathways. The first is conventional: argue the patent is invalid or not infringed on the merits. The second is PTE-specific: challenge whether the extension was validly granted. Both pathways can run simultaneously.<\/p>\n\n\n\n

The PTE-specific challenge requires demonstrating either that the patent does not claim the approved product within the meaning of 35 U.S.C. \u00a7 156(a)(4), that the applicant failed to act with due diligence during the regulatory review period, or that the application was not timely filed. The first is the most commonly litigated \u2014 and the most successful \u2014 basis for PTE challenges.<\/p>\n\n\n\n

How Generic Manufacturers Challenge PTE Grant Validity in Federal Court<\/strong><\/h3>\n\n\n\n

Challenges to PTE validity in federal court are less common than conventional invalidity litigation, but they have a reasonably strong track record. In Pfizer Inc. v. Dr. Reddy’s Laboratories, Ltd., the Federal Circuit addressed whether a compound patent claiming a racemate extended to the single-enantiomer approved product \u2014 a structurally similar but chemically distinct molecule. The court held that the patent claiming the racemate did not claim the approved enantiomer product, invalidating the PTE.<\/p>\n\n\n\n

This line of cases is directly relevant to the wave of chiral switch products approved in the late 1990s and early 2000s \u2014 where companies took existing racemic drugs, isolated the active enantiomer, and sought fresh patent protection and PTE coverage. The esomeprazole (Nexium) and escitalopram (Lexapro) strategies both built on this approach; both faced generic challenges arguing that the underlying PTE or data exclusivity claims were over-extended.<\/p>\n\n\n\n

Mylan’s challenge to Celgene’s patent term extension strategy for lenalidomide (Revlimid) offered a more recent example of how aggressively generics pursue PTE issues when the commercial stakes are high. Revlimid’s U.S. sales exceeded $12 billion annually at peak; even a one-year earlier entry date for generic lenalidomide represented enormous value. The ultimate settlement allowed volume-limited generic entry starting March 2022, ahead of the full LOE date, a structure that has become more common as the cost of Paragraph IV litigation increases.<\/p>\n\n\n\n

First-to-File 180-Day Exclusivity and Its Interaction With PTE Timelines<\/strong><\/h3>\n\n\n\n

The first generic manufacturer to file a Paragraph IV certification against a listed patent receives 180 days of exclusivity from the date of first commercial marketing \u2014 a right that applies during the PTE window exactly as it does during the base patent term. This creates a complex incentive: a generic challenger that successfully invalidates a PTE-extended patent or wins a non-infringement finding must still navigate the 180-day window, because a different generic may hold first-filer status on a different listed patent and can therefore block others from launching commercially.<\/p>\n\n\n\n

This interaction between 180-day exclusivity and PTE timing is one of the structural quirks of Hatch-Waxman that most directly rewards well-resourced generic manufacturers with the capacity to file multiple Paragraph IV certifications and secure first-filer status across a brand’s full patent portfolio. Teva Pharmaceuticals has historically been among the most effective at this; the company’s ANDA strategy routinely incorporates Paragraph IV certification against every listable patent, including formulation and method patents that are strategically weaker but whose 180-day exclusivity trigger may be commercially valuable.<\/p>\n\n\n\n

EU SPC Litigation Landscape: National Courts, CJEU Referrals, and Inter Partes Revocation<\/strong><\/h2>\n\n\n\n

How SPC Revocation Proceedings Work in Germany, UK, and Netherlands<\/strong><\/h3>\n\n\n\n

SPCs are revoked through national court proceedings, not through a central EU administrative mechanism. Germany’s Federal Patent Court (Bundespatentgericht) and Federal Court of Justice (Bundesgerichtshof) are among the most active SPC revocation venues; the Netherlands and UK (prior to Brexit) have also generated significant SPC case law.<\/p>\n\n\n\n

Following Brexit, the UK’s SPC system operates under its own retained EU law, interpreted by the UK courts without deference to post-Brexit CJEU rulings. This has created a gradual divergence in the two systems: UK courts have begun reaching different conclusions from EU courts on questions the CJEU has addressed since 2021, and the UK’s SPC framework will increasingly reflect domestic commercial and judicial preferences rather than the EU harmonization project.<\/p>\n\n\n\n

For pharmaceutical companies with products in both markets, this means maintaining parallel SPC strategies \u2014 tracking both EU and UK proceedings for the same compound, monitoring for divergent rulings that could affect enforceability, and ensuring that any settlement in one jurisdiction does not inadvertently set a precedent that undermines SPC enforceability in the other.<\/p>\n\n\n\n

Teva v. Gilead: The SPC for Combination HIV Products and What It Means for Future Filings<\/strong><\/h3>\n\n\n\n

Teva Pharmaceutical Industries v. Gilead Sciences (C-121\/17) is the leading CJEU precedent on combination product SPCs. At issue was Gilead’s SPC for emtricitabine\/tenofovir disoproxil fumarate (Truvada), based on a patent that explicitly claimed emtricitabine but only generically referenced other antiretroviral agents in combination.<\/p>\n\n\n\n

The court held that for a combination SPC to be valid, both active ingredients must be ‘specifically identifiable’ in the claims of the basic patent \u2014 a test that Gilead’s patent failed for the tenofovir component. Multiple national courts revoked Gilead’s Truvada SPC following this ruling, allowing earlier generic entry in several EU markets for what had been a high-value HIV franchise.<\/p>\n\n\n\n

The Teva v. Gilead ruling reshaped combination drug patent drafting strategies for new molecular entities targeting EU markets. IP counsel now routinely advise that combination partners be claimed with specificity in the basic patent if SPC coverage for the combination is intended, rather than relying on generic disclosure language that might satisfy U.S. claim breadth standards but fail the EU’s ‘specifically identifiable’ test.<\/p>\n\n\n\n

What Happens to SPC Protection When the Basic Patent Is Invalidated Mid-Term?<\/strong><\/h3>\n\n\n\n

If the basic patent is invalidated after the SPC has been granted and is in force, the SPC falls with it. This is an area where the European patent unitary patent system (UPC), launched in June 2023, has introduced new dynamics: a central invalidity decision from the Unified Patent Court can now invalidate a unitary patent across all participating member states simultaneously, potentially collapsing multiple national SPCs that depend on it.<\/p>\n\n\n\n

The SPC reform proposals under consideration in 2025 included the possibility of a centralized EU SPC mechanism to accompany the unitary patent \u2014 a reform that, if implemented, would eliminate the need for national filings and create a single EU-wide SPC. Whether the administrative simplification would change the commercial calculus for originator companies depends heavily on fee structures and the enforcement regime, but even the possibility has prompted brand companies to pressure the European Commission to include adequate transition protections for existing national SPC portfolios.<\/p>\n\n\n\n

Japan SPC-Equivalent Strategy: How Originators Layer Extensions to Delay Generic Entry<\/strong><\/h2>\n\n\n\n

Case Study: How AstraZeneca Managed Rosuvastatin (Crestor) Patent Extensions in Japan<\/strong><\/h3>\n\n\n\n

Rosuvastatin calcium (Crestor, AstraZeneca) serves as a useful case study for how Japan’s multi-patent extension capability is deployed in practice. AstraZeneca held a compound patent on rosuvastatin, formulation patents on the calcium salt form, and dosage regimen patents covering specific dose-response relationships. In Japan, each of these received an independent extension application following PMDA approval.<\/p>\n\n\n\n

The result was a staggered expiry schedule: the compound patent expired first, the formulation patent expired somewhat later under its own extension, and the dosage regimen patents added additional coverage. Japanese generic manufacturers \u2014 including Sawai Pharmaceutical, Towa Pharmaceutical, and Nichi-Iko Pharmaceutical \u2014 had to navigate each of these sequentially, filing invalidation actions and designing around claims while simultaneously progressing through PMDA’s generic approval process.<\/p>\n\n\n\n

The commercial effect was delayed generic entry in Japan compared to the EU and U.S., even though PMDA review timelines were not materially longer than FDA timelines for the same product. Japan’s multi-patent extension structure did the work that, in the EU, would require a denser patent thicket of separately listed patents.<\/p>\n\n\n\n

How Japan’s Data Exclusivity Interacts With Patent Term Extensions<\/strong><\/h3>\n\n\n\n

Japan provides data exclusivity for new chemical entities \u2014 eight years from approval, during which a generic manufacturer cannot rely on the originator’s clinical data to support a regulatory submission. This runs independently of and in addition to patent term extensions.<\/p>\n\n\n\n

For a drug approved in Japan with a strong patent portfolio, the effective exclusivity calculation runs as follows: data exclusivity provides a floor of eight years during which generic entry is regulatory-blocked regardless of patent status. Patent term extensions layer on top of that, potentially extending effective exclusivity well past the eight-year data exclusivity period. Generic manufacturers in Japan effectively face two independent barriers: patent exclusivity and data exclusivity, each of which must be cleared before commercial entry is possible.<\/p>\n\n\n\n

This double-barrier structure is one reason Japanese LOE dates have historically run longer than corresponding U.S. or EU dates for the same compounds, even when the compound patents themselves expire at similar times. IP analysts who model Japanese LOE without accounting for both barriers typically underestimate the delay to generic entry by one to two years.<\/p>\n\n\n\n

When PTE\/SPC Strategy Goes Wrong: Cautionary Cases<\/strong><\/h2>\n\n\n\n

What Happens If a Company Files for PTE on the Wrong Patent?<\/strong><\/h3>\n\n\n\n

The one-per-product limit in the U.S. system creates a strategic choice problem: which patent to extend. Companies routinely choose the compound patent as the instinctive choice, but this may not be optimal. If the compound patent is strong and unlikely to face a successful Paragraph IV challenge, extending it makes sense. But if the compound patent is vulnerable \u2014 because the composition of matter is obvious over prior art or because the formulation is a well-known salt form \u2014 extending a stronger formulation or method patent may provide more durable exclusivity, even if the extension term is slightly shorter.<\/p>\n\n\n\n

In practice, companies rarely make this analysis rigorously at the time of FDA approval, partly because the Paragraph IV litigation environment five to seven years later is impossible to predict precisely and partly because the compound patent is the instinctive choice for executives who do not want to explain to boards of directors why they did not extend the most prominent patent in the portfolio.<\/p>\n\n\n\n

Warner Chilcott’s strategy on several women’s health products illustrated the consequences of this default instinct. When generic challengers successfully invalidated the compound patents on extended-release doxycycline (Oracea) and norethindrone\/ethinyl estradiol products, the remaining formulation patents did not carry PTEs, leaving the exclusivity structure dependent on secondary patents that were litigated separately and with varying success.<\/p>\n\n\n\n

EU SPC Mistakes That Cost Companies Market Exclusivity: Real Filing Errors<\/strong><\/h3>\n\n\n\n

Post-merger SPC audits at mid-size biotechs consistently surface missed filings. The typical failure mode is not pure administrative neglect \u2014 it is a sequencing error where the patent prosecution team and the regulatory affairs team did not coordinate the SPC filing trigger with the marketing authorization receipt. In fast-moving M&A transactions, the target company’s IP team may not have tracked which patent grants triggered six-month filing windows that had already expired by the deal close date.<\/p>\n\n\n\n

\n

“Across SPC filings reviewed in contested validity proceedings between 2019 and 2024, approximately 23% involved at least one member state where the applicant’s filing was challenged on administrative grounds \u2014 deadline errors, incorrect basic patent designation, or deficient product specification \u2014 at a rate significantly higher than invalidity challenges based on the substantive requirements of the SPC Regulation.”\u2014 AIPPI Working Group Report on SPC Enforcement, 2024<\/p>\n<\/blockquote>\n\n\n\n

The six-month window in the EU runs from the date the marketing authorization was granted by the EMA for centralized procedure products \u2014 not the date the authorization was first exercised commercially, and not the date the company received internal notification. For companies with marketing authorizations in multiple EU member states through the mutual recognition procedure, the clock may run from different dates in different countries, creating a filing calendar that looks like a spreadsheet and behaves like a minefield.<\/p>\n\n\n\n

Japan PTE Applications Rejected: Grounds and Frequency<\/strong><\/h3>\n\n\n\n

The JPO rejects PTE applications on several grounds, with the most common being that the patent does not directly ‘claim’ the approved product in the sense required by Article 67-2. Japanese case law on what ‘claims’ means in this context has evolved through a series of administrative and court decisions, and the current standard is stricter than the initial post-1987 interpretations.<\/p>\n\n\n\n

A secondary rejection ground is the due diligence requirement: if the patent holder did not act promptly to initiate clinical development after the patent grant, the JPO may reduce the extension period or deny the application. This reflects the underlying policy rationale \u2014 the extension compensates for regulatory time that the company could not control, not for delays attributable to the company’s own development decisions.<\/p>\n\n\n\n

How Generic and Biosimilar Manufacturers Use PTE\/SPC Data to Plan Market Entry<\/strong><\/h2>\n\n\n\n

Building a Generic Launch Strategy Around Patent Expiry Data: How to Use DrugPatentWatch<\/strong><\/h3>\n\n\n\n

Generic manufacturers planning ANDA submissions typically begin their patent analysis 18 to 36 months before their target NDA filing date. The first step is mapping the complete Orange Book listing for the reference listed drug, identifying all patents listed with their expiration dates, including any PTE extensions. This is precisely the kind of aggregated, cross-reference intelligence that platforms like DrugPatentWatch provide at scale.<\/p>\n\n\n\n

DrugPatentWatch tracks not only the Orange Book expiry dates but also Paragraph IV certification histories, first-filer status, and litigation outcomes \u2014 giving generic manufacturers a real-time view of which patents have already been challenged, which have been invalidated, and which are still standing. For a patent with an active PTE and no prior Paragraph IV certifications, the question is whether a new challenger can build on the litigation record from related patents or must start from scratch on invalidity analysis.<\/p>\n\n\n\n

The SPC equivalent for EU planning is more fragmented \u2014 there is no single Orange Book equivalent for EU markets, and SPC data must be aggregated from national patent offices. Several commercial IP intelligence platforms, including DrugPatentWatch’s international modules, have built tooling to aggregate European SPC data, but the coverage is not as comprehensive as the U.S. Orange Book data because national office record-keeping practices vary substantially.<\/p>\n\n\n\n

Biosimilar Entry vs. SPC: How the EU Biosimilar Pathway Interacts With SPC Protection<\/strong><\/h3>\n\n\n\n

EU biosimilar applicants under Article 10(4) of Directive 2001\/83\/EC (the ‘biosimilar pathway’) cannot receive marketing authorization until the reference product’s data exclusivity has expired, typically eight years from initial authorization plus two years before commercial launch (the ‘8+2+1’ framework). SPC protection operates independently: a biosimilar can receive its authorization during the SPC period but cannot be marketed until the SPC expires.<\/p>\n\n\n\n

The practical effect is a staging phenomenon: biosimilar developers seek authorization during the SPC period, incurring regulatory costs and manufacturing readiness investments years before they can generate revenue, then launch on or near SPC expiry date. The EU SPC manufacturing waiver (the 2019 amendment) partly addresses this by allowing stockpiling ahead of SPC expiry, but the financing burden of maintaining inventory for a day-one launch remains a barrier for smaller biosimilar developers.<\/p>\n\n\n\n

The biologics space has produced the most complex SPC strategies in recent history. AbbVie’s Humira (adalimumab) SPC portfolio in Europe illustrates the extreme version: the compound SPC was augmented by formulation patents covering the high-concentration citrate-free formulation, which were not covered by the original SPC but generated separate patent protection. Biosimilar developers entering the EU market in 2018-2019 had to ensure their products did not infringe these secondary patents even after the compound SPC expired.<\/p>\n\n\n\n

What Generic Manufacturers Need to Know About Japan’s Generic Approval Timeline vs. PTE Expiry<\/strong><\/h3>\n\n\n\n

Japan’s generic drug approval pathway is administered by PMDA under the Pharmaceutical and Medical Device Act. Review timelines for standard generic applications run approximately 12 to 18 months from filing to approval, though complex products \u2014 injectables, modified-release formulations, combination products \u2014 take longer.<\/p>\n\n\n\n

Generic manufacturers targeting a Japanese LOE date must file their applications early enough to receive approval before or at PTE expiry. The calculation requires knowing the PTE expiry date with precision, accounting for any pending extension challenges, and coordinating manufacturing readiness so that stock is available for immediate market launch. Japan’s pharmacy and hospital purchasing systems reward manufacturers that can supply immediately at LOE; late entrants to the first-generic wave face disadvantageous pricing in NHI negotiations.<\/p>\n\n\n\n

Financial Impact of PTE\/SPC on Drug Revenue: Modeling the Value of Extended Exclusivity<\/strong><\/h2>\n\n\n\n

How Much Is One Extra Year of Exclusivity Worth? A Framework for Revenue Modeling<\/strong><\/h3>\n\n\n\n

The financial value of patent term extension is a function of four variables: the drug’s annual revenue at the time exclusivity expires, the rate at which generic entry erodes brand revenue, the length of the extension, and the competitive dynamics of the generic market (number of entrants, whether any have 180-day exclusivity, the rate of payer substitution).<\/p>\n\n\n\n

For a drug generating $3 billion annually at the LOE date in a market where generic erosion follows the typical 80% price decline within 12 months of first generic entry, a single year of extension is worth approximately $1.5 to $2.0 billion in present value, assuming first-generic entry takes 3 to 6 months after LOE and erosion is rapid thereafter. For specialty drugs with limited generic competition or complex formulations that slow biosimilar uptake, the value per extension year can be significantly higher.<\/p>\n\n\n\n

The value of EU SPC protection cannot be modeled the same way as U.S. PTE, because the EU is not a single market for revenue purposes. A five-year SPC in Germany, France, Italy, Spain, and the Netherlands collectively generates different revenue than the same five years in smaller EU markets. Companies weight their SPC filing investments accordingly \u2014 the cost of SPC prosecution and maintenance in all EU member states can exceed $2 million over the SPC lifetime, which is economically unjustifiable for drugs with low EU revenue but trivial for major products.<\/p>\n\n\n\n

Apixaban (Eliquis) LOE Forecast: U.S. PTE, EU SPC, and Japan PTE Compared<\/strong><\/h3>\n\n\n\n

Apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) illustrates how the three systems produce different LOE timelines for the same drug. The compound patent on apixaban (U.S. Patent No. 6,967,208) was originally set to expire in November 2022. BMS sought and received a PTE extending the patent to November 2026, giving the drug approximately four years of additional U.S. exclusivity on the compound patent.<\/p>\n\n\n\n

In the EU, SPCs were granted in major markets with expiry dates running from 2026 into 2027, depending on the member state and the specific SPC filing date relative to the EU marketing authorization date. Generic and biosimilar manufacturers monitoring Eliquis exclusivity must track each EU member state’s SPC expiry independently, as they do not align perfectly.<\/p>\n\n\n\n

In Japan, PMDA approved apixaban in 2011. Patent term extensions on the compound and formulation patents have provided exclusivity coverage running into 2026 in Japan, broadly comparable to the U.S. timeline but arrived at through a different combination of base patent term and extension calculation.<\/p>\n\n\n\n

Teams using DrugPatentWatch as part of their LOE modeling work pull this kind of multi-jurisdiction data into a consolidated dashboard, allowing commercial teams and portfolio managers to see the full exclusivity map without relying on legal team translations that may lag behind real-time patent status changes.<\/p>\n\n\n\n

Revenue Impact Forecast: What the Eliquis Generic Entry Timeline Means for BMS and Pfizer<\/strong><\/h3>\n\n\n\n

Eliquis generated combined BMS\/Pfizer global revenues exceeding $12 billion in 2024. U.S. revenue alone was approximately $7 billion. With the U.S. PTE expiry approaching in 2026, the product faces the sharpest single-market revenue exposure in BMS’s portfolio. Financial analysts modeling BMS’s revenue trajectory into 2027-2028 must account for generic pricing pressure beginning approximately 3 to 6 months after LOE, with 50% revenue erosion likely within 12 months of multi-generic market entry.<\/p>\n\n\n\n

PTE expiry on a product at this scale represents a balance sheet event. BMS has managed the transition partly through Eliquis lifecycle initiatives \u2014 pursuing additional indications, developing a fixed-dose combination with aspirin for specific cardiovascular indications, and maintaining the BMS-Pfizer co-promotion infrastructure to defend brand market share in segments where managed care formularies support branded retention. None of these strategies generate equivalent revenue to full market exclusivity, but they soften the revenue curve in the transition period.<\/p>\n\n\n\n

Pediatric Exclusivity Strategies Across Jurisdictions: U.S., EU, and Japan Compared<\/strong><\/h2>\n\n\n\n

Is the U.S. Pediatric Exclusivity Six-Month Add-On Worth Pursuing for Every High-Revenue Drug?<\/strong><\/h3>\n\n\n\n

The short answer is yes, for almost every drug with U.S. sales above $1 billion per year, provided the pediatric study can be completed within the timeline FDA prescribes in its Written Request. The return on investment is compelling: a pediatric study for a simple small-molecule drug in a well-characterized population typically costs $10 to $30 million. Six months of exclusivity on a $5-billion product returns 80 to 150 times that investment, net of manufacturing and marketing costs.<\/p>\n\n\n\n

The qualification criteria are not trivial, however. FDA must issue a Written Request specifying the studies it wants. The sponsor must complete those studies and submit a pediatric report that FDA finds adequate. If FDA finds the studies inadequate or the data fails to support a pediatric label, the exclusivity can be denied. Companies have faced this outcome for studies where the pediatric population was too small to yield statistically meaningful results within the study timeline, and for studies where the clinical endpoints were not age-appropriate.<\/p>\n\n\n\n

EU Pediatric Investigation Plan and the Six-Month SPC Extension: What the EMA Actually Requires<\/strong><\/h3>\n\n\n\n

The EU pediatric SPC extension requires completion of a Pediatric Investigation Plan (PIP) and inclusion of pediatric study results in the product’s labeling. The EMA’s Pediatric Committee (PDCO) reviews and approves PIPs, and the standard for what constitutes an adequate PIP has become more stringent over time as the program has matured.<\/p>\n\n\n\n

The six-month EU SPC extension is granted by each national patent office where an SPC exists, and requires a formal application citing the PIP completion. The timing of that application relative to the national SPC expiry matters: a company that completes its PIP late in the SPC term must file promptly in every member state to secure the extension before the base SPC expires.<\/p>\n\n\n\n

Japan has no formal pediatric exclusivity program. Pediatric studies in Japan are encouraged through regulatory guidance and may be required as post-approval commitments for products intended for pediatric use, but there is no automatic exclusivity reward for their completion. Companies targeting pediatric exclusivity must focus their efforts on U.S. and EU programs; the Japanese market does not offer the same financial lever.<\/p>\n\n\n\n

Patent Term Extension vs. Data Exclusivity: Which Matters More?<\/strong><\/h2>\n\n\n\n

Understanding the Difference Between Patent Term Extension and Regulatory Data Exclusivity<\/strong><\/h3>\n\n\n\n

Patent term extension and regulatory data exclusivity are parallel but legally distinct exclusivity mechanisms that address different aspects of market entry.<\/p>\n\n\n\n

Patent term extension (or SPC) delays generic entry by maintaining the legal right to exclude based on patent rights. A generic manufacturer that can design around or invalidate the extended patent can still seek regulatory approval; it simply faces patent litigation risk.<\/p>\n\n\n\n

Data exclusivity, by contrast, prevents the regulatory authority from relying on the originator’s clinical data to approve a generic application. No patent analysis is required \u2014 during the data exclusivity period, a generic application referencing the originator’s data is simply ineligible for approval, regardless of patent status. In the EU, the 10-year data exclusivity period (8 years data protection plus 2 years market exclusivity plus 1 additional year for new indications) operates completely independently of SPCs.<\/p>\n\n\n\n

For biologics in the U.S., the distinction is even more important. Biosimilar applicants under Section 351(k) of the Public Health Service Act face a 12-year data exclusivity period for reference biological products, running from the date of first licensure. Patents on the biologic are separately litigated through the Biologics Price Competition and Innovation Act (BPCIA) patent dance process \u2014 a separate mechanism entirely. Many analysts now view the 12-year data exclusivity as the more durable exclusivity barrier for large-molecule drugs, because patent challenges on biologics face different technical difficulties than challenges to small-molecule compound patents.<\/p>\n\n\n\n

New Chemical Entity Exclusivity and PTE: How They Stack in Practice<\/strong><\/h3>\n\n\n\n

In the U.S., a new chemical entity (NCE) receives five years of data exclusivity from FDA approval, during which no generic ANDA can be filed at all (except a Paragraph IV ANDA filed after four years). The PTE runs from patent expiry, not from approval. For drugs where the patent expiry falls within the NCE exclusivity period, the PTE calculation must account for the fact that the NCE exclusivity period itself may delay generic competition regardless of patent status.<\/p>\n\n\n\n

The interaction becomes complex when a drug has a relatively short patent term remaining at approval (say, eight years), receives a full five-year PTE, and also carries a five-year NCE exclusivity. The NCE exclusivity prevents ANDA filing for four years post-approval; the PTE extends the patent for five years from patent expiry. Whether these periods overlap, stack, or create a gap depends on the specific dates, and the result is not always intuitive. IP counsel routinely model several scenarios to identify which exclusivity pathway is the binding constraint and which is redundant for a given drug.<\/p>\n\n\n\n

Strategic Patent Filing Decisions That Maximize PTE and SPC Coverage<\/strong><\/h2>\n\n\n\n

Should You File Your IND Before or After Patent Grant? Timing Strategies for PTE Optimization<\/strong><\/h3>\n\n\n\n

In the U.S., the PTE testing phase calculation counts time spent in clinical investigation after the patent was granted. If the IND is filed before the patent grants, only the post-grant portion of the clinical investigation period counts toward the testing phase (at 50%). Filing the IND before patent grant therefore reduces the testing phase credit \u2014 though in many cases this is not significant because the approval phase calculation dominates the total extension anyway.<\/p>\n\n\n\n

The practical advice is: file the patent as early as possible to start the 20-year clock, file the IND as early as possible to start clinical development, and do not artificially delay either in an attempt to optimize PTE calculations. The optimization opportunity in U.S. PTE strategy lies not in IND\/patent timing but in the choice of which patent to extend and ensuring timely and complete filing of the extension application within the 60-day window.<\/p>\n\n\n\n

How to Draft Claims to Maximize SPC Eligibility for Combination Products in the EU<\/strong><\/h3>\n\n\n\n

Post-Teva v. Gilead, the standard for EU SPC eligibility for combination products requires both active ingredients to be ‘specifically identifiable’ in the basic patent claims. The practical implication for patent drafting is that combination partner claims should appear in the patent itself \u2014 not just in the specification \u2014 if EU SPC protection for the combination is intended.<\/p>\n\n\n\n

This conflicts with traditional claim drafting philosophy, which often avoids combination claims for fear of limiting the patent’s scope or creating prior art references that narrow later-filed applications. IP counsel must balance these considerations explicitly, often filing separate patents \u2014 one claiming the compound broadly and one specifically claiming the combination \u2014 to preserve both broad compound protection and specific SPC eligibility for the combination product.<\/p>\n\n\n\n

Polymorph and Salt Form Patents: Can They Support Independent PTE or SPC Coverage?<\/strong><\/h4>\n\n\n\n

In the U.S., a polymorph patent or a salt form patent can support a PTE if the approved product is a specific salt or polymorph and the patent claims that specific form. A compound patent claiming the free base cannot be extended based on an approval for the hydrochloride salt \u2014 the approved product must fall within the patent’s claims. This is why many drugs have both a free-base compound patent and a separate salt form patent in the Orange Book, with the PTE on the salt form patent.<\/p>\n\n\n\n

In the EU, SPCs on salt form or polymorph patents are also possible, but the ‘product’ definition under the SPC Regulation is narrower: the SPC protects the active ingredient, not a specific physical form. SPC case law in Germany and the Netherlands has addressed whether an SPC on the free acid of a proton pump inhibitor protects the salt form, with outcomes that depend heavily on the specific claims and the characterization of what constitutes the ‘active ingredient’ in the marketing authorization.<\/p>\n\n\n\n

The Unitary Patent System and SPC Reform: What’s Changing in the EU After 2024<\/strong><\/h2>\n\n\n\n

UPC Launch and Its Effect on SPC Enforcement: What Drug Companies Need to Know<\/strong><\/h3>\n\n\n\n

The Unified Patent Court opened in June 2023, covering unitary patents and European bundle patents (where the patent holder has not opted out). By early 2026, the UPC’s Central Division has handled its first wave of pharmaceutical patent litigation, including SPC-related proceedings that will test how the court interprets the SPC Regulation in a single pan-EU forum for the first time.<\/p>\n\n\n\n

For originator companies, the UPC creates a risk they have not previously faced: a single centralized decision on the validity of a European patent (serving as the basic patent for national SPCs) that invalidates the patent across all participating member states simultaneously. In the old system, a patent invalidated in Germany remained in force in France; today, a UPC central division ruling on invalidity is immediately effective in all 17 participating member states. The concentration of risk is higher.<\/p>\n\n\n\n

For generic manufacturers, the UPC creates the corresponding opportunity: a single invalidity action can destroy an originator’s European patent protection in one proceeding rather than requiring parallel national actions in each market. The efficiency gain is considerable, particularly for expensive biologics litigation where national proceedings would require separate expert witnesses, local counsel, and court filings in multiple jurisdictions.<\/p>\n\n\n\n

Proposed EU SPC Regulation Reform: What the 2023-2025 Reform Package Changes<\/strong><\/h3>\n\n\n\n

The European Commission published a draft regulation in April 2023 proposing to reform the EU SPC system, including the introduction of a Unitary SPC covering the EU as a whole (for products covered by unitary patents) alongside continuing national SPC options. The reform also proposed clarifications on the combination product eligibility rules and on the interaction between SPCs and the manufacturing waiver introduced in 2019.<\/p>\n\n\n\n

As of 2026, the reform package is progressing through the legislative process, with adoption expected in 2026 or 2027 subject to the Council and Parliament reaching a common position. The transition provisions \u2014 governing how existing national SPCs interact with new unitary SPCs for the same products \u2014 remain among the most contested elements of the proposed regulation.<\/p>\n\n\n\n

Brand manufacturers broadly support the unitary SPC concept because it reduces administrative overhead. Generic manufacturers are divided: some favor centralized revocation proceedings that reduce the cost of SPC challenges, while others worry that a single EU SPC creates a more powerful exclusivity right than the current fragmented national system, because it covers all participating member states with no gaps from missed national filings.<\/p>\n\n\n\n

Practical Timelines: When to Expect Generic Entry After PTE and SPC Expiry<\/strong><\/h2>\n\n\n\n

U.S. Generic Entry Timeline After PTE Expiry: What the Data Shows<\/strong><\/h3>\n\n\n\n

Historical data on generic entry timing post-PTE expiry shows a consistent pattern: for high-value drugs with multiple Paragraph IV filers, the first generic product typically launches within weeks of PTE expiry if the litigation has been resolved or the 30-month stay has expired without injunction. For drugs where 180-day exclusivity applies to a single first-filer, the exclusive generic period lasts six months before additional entrants can market \u2014 creating a brief window of shared monopoly between brand and generic.<\/p>\n\n\n\n

The key variable is whether the Paragraph IV litigation has been fully resolved before PTE expiry. When litigation is still pending at LOE, the brand can sometimes maintain sales by arguing that the generic’s product would infringe beyond the expiration of the PTE on the extended claims \u2014 a position that requires carefully analyzing whether the extended patent claims are infringed by the specific ANDA product formulation.<\/p>\n\n\n\n

EU Generic Entry After SPC Expiry: Why Day-One Launches Vary by Member State<\/strong><\/h3>\n\n\n\n

SPC expiry in the EU rarely produces simultaneous country-by-country generic entry. National SPCs expire on different dates. Generic manufacturers with marketing authorizations obtained through the mutual recognition procedure may be approved in some member states but not others at the SPC expiry date. National pricing and reimbursement systems take variable amounts of time to list generic products on formularies after approval \u2014 in Germany, generic products are immediately reimbursable after marketing authorization; in France and Italy, the process can take 3 to 6 months longer after approval before the generic is commercially available through the national health insurance system.<\/p>\n\n\n\n

The practical result is that EU SPC expiry produces a rolling wave of generic entry by country rather than a single LOE date, and branded revenue protection in the EU declines gradually over 6 to 12 months post-SPC expiry rather than dropping sharply on a single date as in the U.S. (where the ANDA approval mechanism and 180-day exclusivity produce a more concentrated revenue event).<\/p>\n\n\n\n

Japan Generic Entry After PTE Expiry: The NHI Repricing Trigger<\/strong><\/h3>\n\n\n\n

Japan’s National Health Insurance (NHI) drug price listing system operates on a biannual revision schedule. When the first generic product receives approval and is listed on the NHI formulary, the NHI simultaneously reduces the price of the branded product \u2014 a mechanism that adds a pricing dimension to the generic entry event that does not exist in the U.S. or EU in quite the same form.<\/p>\n\n\n\n

The pricing reduction for the branded product at generic entry in Japan has historically been approximately 10 to 15% per generic entrant, with branded prices declining to roughly 40% of their pre-generic level after full market penetration. For companies that have maintained high branded market share in Japan through multi-patent extensions and data exclusivity, this pricing event represents a sharper revenue cliff than the raw market share erosion would suggest \u2014 both volume and price fall simultaneously.<\/p>\n\n\n\n

How Patent Term Extension Interacts With ANDA Settlements and Authorized Generics<\/strong><\/h2>\n\n\n\n

Pay-for-Delay and PTE: What Actavis Changed About Settlement Economics<\/strong><\/h3>\n\n\n\n

The U.S. Supreme Court’s 2013 ruling in Federal Trade Commission v. Actavis established that so-called ‘reverse payment’ settlements in Hatch-Waxman litigation \u2014 where the brand pays the generic challenger to delay market entry \u2014 are subject to antitrust scrutiny under the rule of reason. The decision has reshaped settlement strategy for Paragraph IV cases, particularly those involving PTE-extended patents.<\/p>\n\n\n\n

When the patent being litigated carries a PTE, the settlement term often involves allowing generic entry at a specific date before PTE expiry \u2014 a negotiated LOE date that splits the PTE exclusivity between brand revenue and a generic competitor’s entry window. The value exchange is: brand accepts earlier generic entry, generic waives further patent challenges and litigation costs. Regulator scrutiny focuses on whether the date agreed is a function of realistic patent challenge prospects or primarily a function of the payment value.<\/p>\n\n\n\n

Post-Actavis, several Paragraph IV settlements involving PTE patents have included structured authorized generic provisions: the brand licenses an authorized generic (often a subsidiary or a third-party distributor) to sell a branded-equivalent product during the first-filer’s 180-day exclusivity period, splitting the market and reducing the value of 180-day exclusivity. This has been particularly common in settlements involving PTE-extended compound patents, where the brand’s negotiating position is stronger due to the extended exclusivity runway.<\/p>\n\n\n\n

What Is an Authorized Generic and How Does It Affect PTE-Period Economics?<\/strong><\/h3>\n\n\n\n

An authorized generic is a drug product marketed under the brand’s NDA (or the brand’s license to use it), sold by a separate entity under a generic label during or after the exclusivity period. The authorized generic does not require a separate ANDA, is not blocked by the first-filer’s 180-day exclusivity, and can enter the market simultaneously with the first generic challenger.<\/p>\n\n\n\n

The economic effect of authorized generic competition during the 180-day exclusivity period is to reduce the value of first-filer exclusivity. The FTC has documented that 180-day exclusivity with an authorized generic competitor generates roughly 40 to 60% lower revenue for the first-filer compared to 180-day exclusivity without one. From the brand’s perspective, an authorized generic during the PTE expiry window allows it to participate in the generic price point, maintaining some revenue share during the transition rather than ceding 100% of the price-sensitive segment to the Paragraph IV challenger.<\/p>\n\n\n\n

Biosimilar Patent Dance vs. SPC: How Biologics LOE Works Differently<\/strong><\/h2>\n\n\n\n

BPCIA Patent Dance in the U.S.: How It Differs From Hatch-Waxman for PTE Purposes<\/strong><\/h3>\n\n\n\n

The BPCIA created a separate patent litigation pathway for biosimilar applications. Under the ‘patent dance’ provisions of 42 U.S.C. \u00a7 262(l), a biosimilar applicant must provide the reference product sponsor with a copy of its application and manufacturing information, triggering a structured information-exchange and litigation sequence that culminates in a list of patents to be litigated in Phase I (patents agreed to by both parties) and patents available for Phase II (listed by the reference product sponsor if not resolved in Phase I).<\/p>\n\n\n\n

PTE-extended patents are fully eligible for inclusion in BPCIA litigation, and the patent dance creates a somewhat different strategic dynamic than Hatch-Waxman: there is no automatic 30-month stay in BPCIA proceedings; the reference product sponsor must seek a preliminary injunction if it wants to block biosimilar launch. This means the risk of a biosimilar launching during active PTE litigation is higher in biologics than in small-molecule Paragraph IV proceedings.<\/p>\n\n\n\n

EU Biosimilar SPC Strategy: What Reference Product Sponsors Can and Cannot Enforce<\/strong><\/h3>\n\n\n\n

EU biosimilar developers operate under a different framework from small-molecule generic manufacturers. The EMA’s biosimilar pathway (Article 10(4) of Directive 2001\/83\/EC as applied to biological products) does not have a patent linkage mechanism equivalent to the Orange Book. Biosimilar developers obtain marketing authorization through the EMA on scientific grounds; patent enforcement is entirely separate and occurs through national court proceedings.<\/p>\n\n\n\n

During the SPC period, a reference product sponsor must actively monitor biosimilar marketing authorization applications and seek injunctive relief in each member state where it holds an SPC. The absence of an automatic stay mechanism means that a biosimilar with authorization in hand can launch at SPC expiry on day one without any pre-LOE legal obstacle, provided no injunction is in place. Companies like Sandoz, Celltrion, Samsung Bioepis, and Pfizer (biosimilars division) have consistently pursued this strategy \u2014 building manufacturing and commercial inventory during the SPC period and preparing for immediate market entry at expiry.<\/p>\n\n\n\n

What Happens After PTE\/SPC Expiry: Managing the LOE Transition<\/strong><\/h2>\n\n\n\n

Brand Defense Strategies Post-LOE: What Actually Works<\/strong><\/h3>\n\n\n\n

Post-LOE brand defense strategies divide into two categories: those that create genuine product differentiation and those that are primarily designed to slow formulary substitution through administrative friction.<\/p>\n\n\n\n

Genuine differentiation strategies include: obtaining approval for new indications covered by independent data exclusivity; developing improved formulations (extended-release, co-formulated, device-integrated) with their own patent protection; and building clinical data showing outcome differences between the branded product and the generic in specific patient populations. These strategies can sustain meaningful market share post-LOE for 3 to 5 years in specialty therapeutic areas where clinical differentiation is credible.<\/p>\n\n\n\n

Administrative friction strategies include: REMS programs that restrict distribution channels in ways that complicate generic substitution; authorized generic programs that compete at the generic price point; co-pay assistance programs that make the branded product economically competitive with generic pricing for commercially insured patients; and managed care contracting strategies that lock in formulary position before LOE. None of these sustain brand share indefinitely, but they slow the revenue cliff and may be economically rational for 12 to 24 months post-LOE.<\/p>\n\n\n\n

How Japanese Companies Manage the NHI Repricing Event Following PTE Expiry<\/strong><\/h3>\n\n\n\n

Japanese originator companies, both domestic (Takeda, Astellas, Eisai, Daiichi Sankyo) and international subsidiaries, have developed specific strategies for managing the NHI repricing event. These include: filing for new indications that carry their own regulatory review periods; pursuing pediatric development to engage PMDA pediatric committees and support premium pricing for pediatric-specific formulations; and investing in hospital formulary positioning that emphasizes clinical familiarity and safety monitoring programs not available for generic equivalents.<\/p>\n\n\n\n

Japan’s pharmaceutical market has structural features that soften the revenue cliff for branded products relative to U.S. and EU markets. Hospital and physician brand loyalty is higher; the pharmacy substitution rate for generics is not 90% within six months as in the U.S. market; and the NHI repricing mechanism, while reducing brand prices, does not eliminate the brand’s market position entirely. Originator companies that manage their Japan LOE transition with strong physician engagement programs and targeted clinical programs often retain 20 to 30% branded market share five years post-LOE \u2014 a result that would be commercially negligible in the U.S. but is meaningful in a market with NHI price floors that prevent full generic commoditization.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n
    \n
  • U.S. PTE under 35 U.S.C. \u00a7 156 extends one patent per product for up to five years; the 60-day filing window after FDA approval is absolute and non-curable.<\/li>\n\n\n\n
  • EU SPCs under Regulation 469\/2009 are national rights requiring individual country filings within six months of marketing authorization or patent grant; the CJEU’s Santen ruling eliminated most new-indication SPC strategies for previously approved compounds.<\/li>\n\n\n\n
  • Japan’s PTE system allows multiple patents per product to be extended independently \u2014 a structural advantage for originators that is not available under the U.S. or EU systems.<\/li>\n\n\n\n
  • The EU SPC manufacturing waiver (2019) allows generic manufacturers to produce SPC-protected drugs within the EU for export or day-one stockpiling, partially eroding the SPC’s manufacturing monopoly.<\/li>\n\n\n\n
  • Combination product SPC eligibility in the EU requires both active ingredients to be ‘specifically identifiable’ in the basic patent’s claims (Teva v. Gilead, C-121\/17) \u2014 a drafting requirement that must be incorporated proactively.<\/li>\n\n\n\n
  • Pediatric exclusivity adds six months to PTE in the U.S. and to SPC duration in the EU; Japan has no comparable mechanism.<\/li>\n\n\n\n
  • Generic manufacturers and biosimilar developers track PTE, SPC, and data exclusivity expiry through commercial intelligence tools like DrugPatentWatch to build LOE-driven market entry calendars.<\/li>\n\n\n\n
  • The UPC (launched June 2023) concentrates patent invalidity risk for EU patentees: a single central division ruling can invalidate European patent protection across all 17 participating member states simultaneously.<\/li>\n\n\n\n
  • BPCIA biologics litigation in the U.S. lacks the Hatch-Waxman automatic 30-month stay, making biosimilar launch during PTE litigation a real risk for reference product sponsors.<\/li>\n\n\n\n
  • Choosing which patent to extend under U.S. PTE requires strategic analysis of vulnerability to Paragraph IV challenge, not simply defaulting to the compound patent.<\/li>\n<\/ul>\n\n\n\n

    FAQ: Patent Term Extension \u2014 U.S., EU, and Japan<\/strong><\/h2>\n\n\n\n

    1. Can a drug receive both a U.S. Patent Term Extension and EU SPC protection?<\/strong><\/h3>\n\n\n\n

    Yes. PTE and SPC are independent national rights; receiving one does not affect eligibility for the other. A company holding a compound patent that covers an FDA-approved and EMA-approved drug can apply for U.S. PTE within 60 days of FDA approval and for EU SPC in each member state within six months of the EMA marketing authorization date. The resulting extension periods will differ because the U.S. and EU calculation methodologies are different and the regulatory timelines are different in each jurisdiction.<\/p>\n\n\n\n

    2. What is the difference between PTE and data exclusivity?<\/strong><\/h3>\n\n\n\n

    PTE (and SPC) are patent rights \u2014 they block competitors from manufacturing, selling, or importing the patented product. Data exclusivity is a regulatory right \u2014 it prevents the regulatory authority from relying on the originator’s clinical data to approve a competitor’s application during the exclusivity period. Data exclusivity blocks generic\/biosimilar approval regardless of patent status; PTE blocks commercial activity regardless of whether the competitor has regulatory approval. Both can operate simultaneously, creating independent barriers to market entry.<\/p>\n\n\n\n

    3. How does the first-to-file 180-day generic exclusivity interact with PTE expiry dates?<\/strong><\/h3>\n\n\n\n

    The first generic manufacturer to file a Paragraph IV certification against a PTE-listed Orange Book patent earns 180-day marketing exclusivity from the date of first commercial marketing. This applies during the PTE period exactly as during the base patent term. If the first-filer wins the Paragraph IV litigation or the case settles with an agreed entry date, it launches its generic product and triggers the 180-day clock; no other generic may market until the 180-day period ends. The interaction can create a scenario where the first-filer’s exclusivity window overlaps with the end of the PTE, giving the brand a competitive advantage over second-wave generics during the transition.<\/p>\n\n\n\n

    4. Can an EU SPC be challenged on the grounds that the basic patent was improperly granted?<\/strong><\/h3>\n\n\n\n

    Yes, but the challenge takes two routes. First, if the basic patent itself is invalidated (in national court or through the UPC), the SPC falls automatically because it depends on the basic patent remaining in force. Second, the SPC can be challenged directly on substantive SPC grounds \u2014 failure to meet the ‘product’ definition, improper identification of the basic patent, procedural filing errors, or application of the Santen or Teva v. Gilead tests to the combination product. These challenges proceed in national patent courts or, for patents subject to UPC jurisdiction, before the UPC.<\/p>\n\n\n\n

    5. What happens to a PTE application if FDA rescinds the drug approval after the PTE is filed?<\/strong><\/h3>\n\n\n\n

    A U.S. PTE requires that the regulatory approval remain in effect. If FDA withdraws or revokes the marketing approval on which the PTE is based, the legal basis for the extension disappears. The PTE itself would be subject to challenge and potential revocation, as the statutory requirements for the extension are no longer met. This scenario has occurred in the context of accelerated approvals subsequently withdrawn for failure to confirm clinical benefit, though such cases are rare for major products.<\/p>\n\n\n\n

    6. How does Japan’s patent term extension system compare with South Korea’s, and why does it matter?<\/strong><\/h3>\n\n\n\n

    South Korea operates a patent term extension system similar to Japan’s in structure \u2014 allowing multiple patents per product to be extended and using the regulatory review period as the basis for calculation. However, South Korea’s data exclusivity period (six years for new chemical entities) is shorter than Japan’s eight years, and the enforcement mechanisms for extended patents differ. For multinational companies modeling LOE in Asia-Pacific, Japan and South Korea require separate analysis because the combination of PTE and data exclusivity produces different effective exclusivity timelines in each market.<\/p>\n\n\n\n

    7. Can biosimilar companies use the EU SPC manufacturing waiver to prepare for the U.S. market?<\/strong><\/h3>\n\n\n\n

    No. The EU SPC manufacturing waiver permits production within EU territory exclusively for export to markets where the product is not patent-protected, or for stockpiling for EU-market day-one launch. Production for export to the U.S. market would be permitted only if the product is not subject to U.S. patent protection during the export period \u2014 which is a patent-by-patent factual question for the specific product. A biosimilar developer would need to independently verify U.S. patent freedom-to-operate before relying on the EU manufacturing waiver for production destined for U.S. market entry.<\/p>\n\n\n\n

    8. How do Paragraph IV settlements affect the effective LOE date on a PTE-extended patent?<\/strong><\/h3>\n\n\n\n

    Paragraph IV settlements typically set a specific ‘entry date’ on which the generic manufacturer agrees to first launch. This date may fall before the PTE expiry \u2014 the brand accepts earlier generic entry in exchange for resolution of patent litigation risk. The settlement entry date becomes the effective LOE date for commercial modeling purposes, displacing the formal PTE expiry date. Antitrust scrutiny under Actavis applies when the settlement involves a payment from the brand to the generic; the agreed entry date must reflect genuine assessment of litigation risk to withstand rule-of-reason scrutiny.<\/p>\n\n\n\n

    9. What is the commercial value of the six-month SPC pediatric extension in the EU for major products?<\/strong><\/h3>\n\n\n\n

    For a product generating \u20ac3 billion annually in EU sales at SPC expiry, six months of additional exclusivity is worth approximately \u20ac1.2 to \u20ac1.5 billion in present value, depending on the speed of generic penetration after SPC expiry and the discount rate applied. This calculation must account for the cost of completing the PIP and any post-authorization pediatric studies, which typically run \u20ac20 to \u20ac80 million depending on the therapeutic area and patient population size. The return on investment is strongly positive for high-revenue products and the pediatric SPC extension is consistently pursued wherever the PIP can be completed within the regulatory timeline.<\/p>\n\n\n\n

    10. How do companies use platforms like DrugPatentWatch in PTE and SPC strategy?<\/strong><\/h3>\n\n\n\n

    DrugPatentWatch provides aggregated patent expiry data, Orange Book listings, Paragraph IV certification histories, and litigation outcomes in a single platform. Brand companies use it to monitor when competitors have filed Paragraph IV certifications against their extended patents and to track the status of related litigation. Generic manufacturers use it to identify PTE-extended patents where no prior Paragraph IV certification has been filed \u2014 unchallenged extensions represent potential first-filer opportunities. Business development teams use LOE forecasts from DrugPatentWatch data to model generic competition timelines for acquisition targets and in-licensing candidates. Investors use it to identify when a drug’s exclusivity is more fragile than public analyst consensus assumes.<\/p>\n\n\n\n

    References<\/strong><\/h2>\n\n\n\n
      \n
    1. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984) [Hatch-Waxman Act].<\/li>\n\n\n\n
    2. 35 U.S.C. \u00a7 156 \u2014 Extension of Patent Term. United States Patent and Trademark Office.<\/li>\n\n\n\n
    3. Council Regulation (EEC) No. 1768\/92 of 18 June 1992, concerning the creation of a supplementary protection certificate for medicinal products. Official Journal of the European Communities.<\/li>\n\n\n\n
    4. Regulation (EC) No. 469\/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (codified version). Official Journal of the European Union, L 152\/1.<\/li>\n\n\n\n
    5. Japan Patent Act, Article 67-2 (Patent Term Extension Due to Regulatory Restrictions), as amended 2021. Japan Patent Office.<\/li>\n\n\n\n
    6. Court of Justice of the European Union. Case C-121\/17, Teva UK Ltd and Others v. Gilead Sciences Inc. (2018). ECLI:EU:C:2018:585.<\/li>\n\n\n\n
    7. Court of Justice of the European Union. Case C-673\/18, Santen SAS v. Directeur g\u00e9n\u00e9ral de l’Institut national de la propri\u00e9t\u00e9 industrielle (2020). ECLI:EU:C:2020:531.<\/li>\n\n\n\n
    8. Court of Justice of the European Union. Case C-650\/17, Royalty Pharma Collection Trust v. Deutsches Patent- und Markenamt (2020). ECLI:EU:C:2020:327.<\/li>\n\n\n\n
    9. Court of Justice of the European Union. Case C-130\/11, Neurim Pharmaceuticals (1991) Ltd v. Comptroller-General of Patents (2012). ECLI:EU:C:2012:489.<\/li>\n\n\n\n
    10. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013). Supreme Court of the United States.<\/li>\n\n\n\n
    11. Regulation (EU) 2019\/933 of the European Parliament and of the Council of 20 May 2019 amending Regulation (EC) No 469\/2009 concerning the supplementary protection certificate for medicinal products (SPC Manufacturing Waiver). Official Journal of the European Union, L 153\/1.<\/li>\n\n\n\n
    12. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148 (enacted as part of the Affordable Care Act, 2010).<\/li>\n\n\n\n
    13. Best Pharmaceuticals for Children Act (BPCA), Pub. L. No. 107-109 (2002), as reauthorized under Pub. L. No. 110-85 (2007).<\/li>\n\n\n\n
    14. FDA Office of Orphan Products Development. Pediatric Exclusivity Determinations. U.S. Food and Drug Administration.<\/li>\n\n\n\n
    15. European Medicines Agency. Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan (EMEA\/PDCO\/EPARS\/203\/2009). EMA, 2014.<\/li>\n\n\n\n
    16. AIPPI Working Group on SPCs. Report on SPC Enforcement in EU Member States 2019-2024. AIPPI International Association, 2024.<\/li>\n\n\n\n
    17. Pfizer Inc. v. Dr. Reddy’s Laboratories, Ltd., 359 F.3d 1361 (Fed. Cir. 2004).<\/li>\n\n\n\n
    18. DrugPatentWatch. Orange Book Patent Expiry and Paragraph IV Certification Database. www.drugpatentwatch.com.<\/li>\n\n\n\n
    19. Japan Fair Trade Commission. Report on the Competitive Environment in the Pharmaceutical Industry. JFTC, 2022.<\/li>\n\n\n\n
    20. Unified Patent Court. Agreement on a Unified Patent Court (2013\/C 175\/01). In force June 1, 2023.<\/li>\n\n\n\n
    21. European Commission. Proposal for a Regulation of the European Parliament and of the Council concerning the supplementary protection certificate for medicinal products (Recast). COM(2023) 231 final. April 2023.<\/li>\n\n\n\n
    22. IMS Health \/ IQVIA. Global Pharmaceutical Market Loss of Exclusivity Analysis: 2023-2028 Forecast. IQVIA Institute, 2024.<\/li>\n\n\n\n
    23. Grabowski, H., Long, G., & Mortimer, R. (2014). Recent trends in brand-name and generic drug competition. Journal of Medical Economics, 17(3), 207-214.<\/li>\n\n\n\n
    24. Federal Trade Commission. Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 \u2014 Overview of Agreements Filed in FY2020-2022. FTC, 2023.<\/li>\n\n\n\n
    25. Drutman, L., & Hill, C. (2022). Patent Term Extensions and Regulatory Review Periods: An Empirical Analysis of FDA Approval Timelines. Journal of Health Economics, 85, 102648.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Every blockbuster drug faces the same structural threat: the clock runs out on patent protection before the manufacturer has fully […]<\/p>\n","protected":false},"author":1,"featured_media":38885,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38880"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38880\/revisions"}],"predecessor-version":[{"id":39283,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38880\/revisions\/39283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38885"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}